In Utero Exposure to Selective Serotonin Reuptake Inhibitors and Risk for Autism Spectrum Disorder
- 1.5k Downloads
We investigated whether there is an association between increased risk for autism spectrum disorders (ASD) and selective serotonin reuptake inhibitors (SSRIs) used during pregnancy. This study used Denmark’s health and population registers to obtain information regarding prescription drugs, ASD diagnosis, and health and socioeconomic status. There were 1.5 % of cases and 0.7 % of controls exposed to SSRIs during the pregnancy period, and higher effect estimates observed with longer use. We found evidence that in utero exposure to SSRIs increases a child’s risk associated with ASD. These results, while adding to the limited knowledge on prenatal pharmacological exposures as potential ASD risk factors, need to be balanced against the benefits of indicated medication use by pregnant mothers.
KeywordsAutism spectrum disorders Selective serotonin reuptake inhibitors Pregnancy Depression
We thank Karyn Heavner, Ph.D., for assisting with data management, and implementation of Monte Carlo simulations. Fees to access Denmark’s national’s registers were funded by Drexel University Department of Epidemiology and Biostatistics (Dr. Newschaffer). Dr. Gidaya’s travel was funded in part through a travel award through Drexel University.
Conflict of interest
All authors and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.
- Bakker, M. K., Kerstjens-Frederikse, W. S., Buys, C. H., de Walle, H. E., & de Jong-van den Berg, L. T. (2010). First-trimester use of paroxetine and congenital heart defects: A population-based case–control study. Birth Defects Research Part A: Clinical and Molecular Teratology, 88, 94–100.Google Scholar
- Bakker, M. K., Kolling, P., van den Berg, P. B., de Walle, H. E., & de Jong van den Berg, L. T. (2008). Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. British Journal of Clinical Pharmacology, 65, 600–606.PubMedCrossRefPubMedCentralGoogle Scholar
- Carter, A. S., Garrity-Rokous, F. E., Chazan-Cohen, R., Little, C., & Briggs-Gowan, M. J. (2001). Maternal depression and comorbidity: Predicting early parenting, attachment security, and toddler social–emotional problems and competencies. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 18–26.PubMedCrossRefGoogle Scholar
- Cooper, W. O., Willy, M. E., Pont, S. J., & Ray, W. A. (2007). Increasing use of antidepressants in pregnancy. American Journal of Obstetrics and Gynecology, 196(544), e1–e5.Google Scholar
- Huot, R. L., Brennan, P. A., Stowe, Z. N., Plotsky, P. M., & Walker, E. F. (2004). Negative affect in offspring of depressed mothers is predicted by infant cortisol levels at 6 months and maternal depression during pregnancy, but not postpartum. Annals of the New York Academy of Sciences, 1032, 234–236.PubMedCrossRefGoogle Scholar
- Jimenez-Solem, E., et al. (2012). Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: A nationwide cohort study. BMJ Open, 2, 1–9.Google Scholar
- Weikum, W. M., Oberlander, T. F., Hensch, T. K., & Werker, J. F. (2012). Prenatal exposure to antidepressants and depressed maternal mood alter trajectory of infant speech perception. Proceedings of the National Academy of Sciences of the USA, 109(Suppl 2), 17221–17227.PubMedCrossRefPubMedCentralGoogle Scholar
- Yudell, M., Tabor, H. K., Dawson, G., Rossi, J., Newschaffer, C. (2013). Priorities for autism spectrum disorders risk communication and ethics. Autism, 17(6), 701–722.Google Scholar